Multiple Myeloma Treatment Outcomes May Improve with ‘Next-Generation Drug Candidates’, Review Says
Advances in the molecular understanding of multiple myeloma (MM)…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreAdvances in the molecular understanding of multiple myeloma (MM)…
Results from a clinical trial support the use of…
Takeda Pharmaceutical Company Limited has recently received a negative…
The Advanced Practitioners Society for Hematology and Oncology…
Amgen reported findings from a post-hoc analysis of the pivotal Phase…
Researchers from Janssen Research & Development presented promising interim…